应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ADCT ADC Therapeutics SA
盘后交易 03-02 16:49:40 EST
4.18
+0.08
+1.95%
盘后
4.18
+0.00
0.00%
16:40 EST
最高
4.22
最低
3.94
成交量
52.08万
今开
4.02
昨收
4.10
日振幅
6.83%
总市值
5.18亿
流通市值
3.86亿
总股本
1.24亿
成交额
215.06万
换手率
0.56%
流通股本
9,224万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
ADC Therapeutics SA:若发生控制权变更,收购方将继续支付特许权使用费直至达到原定上限
美股速递 · 02-23
ADC Therapeutics SA:若发生控制权变更,收购方将继续支付特许权使用费直至达到原定上限
ADC Therapeutics SA预计2027年起实现显著增长,美国市场潜在年收入峰值或达6亿至10亿美元
美股速递 · 02-23
ADC Therapeutics SA预计2027年起实现显著增长,美国市场潜在年收入峰值或达6亿至10亿美元
ADC Therapeutics SA获医疗保健特许权公司授予认股权证 可购买约980万股普通股 行权价每股3.81美元
美股速递 · 02-23
ADC Therapeutics SA获医疗保健特许权公司授予认股权证 可购买约980万股普通股 行权价每股3.81美元
Adc Therapeutics Sa盘中异动 早盘快速下跌5.01%报3.41美元
市场透视 · 01-28
Adc Therapeutics Sa盘中异动 早盘快速下跌5.01%报3.41美元
ADC Therapeutics SA - 出售股东可能不时提供14,696,253股普通股 - SEC备案
美股速递 · 2025-12-13
ADC Therapeutics SA - 出售股东可能不时提供14,696,253股普通股 - SEC备案
ADC Therapeutics 发布 Lotis-7 1B期临床试验的新数据,显示 Zynlonta® 与双特异性抗体联合使用的潜在最佳治疗方案,适用于复发/难治性大B细胞淋巴瘤患者
美股速递 · 2025-12-03
ADC Therapeutics 发布 Lotis-7 1B期临床试验的新数据,显示 Zynlonta® 与双特异性抗体联合使用的潜在最佳治疗方案,适用于复发/难治性大B细胞淋巴瘤患者
ADC Therapeutics 2025财年Q3业绩会总结及问答精华:ZENLATA临床进展与市场扩展潜力
业绩会速递 · 2025-11-10
ADC Therapeutics 2025财年Q3业绩会总结及问答精华:ZENLATA临床进展与市场扩展潜力
ADC Therapeutics SA:截至9月30日的三个月和九个月内,重组、减值及其他相关费用分别为40万美元和1350万美元
美股速递 · 2025-11-10
ADC Therapeutics SA:截至9月30日的三个月和九个月内,重组、减值及其他相关费用分别为40万美元和1350万美元
Adc Therapeutics Sa盘中异动 股价大跌5.16%报1.75美元
市场透视 · 2025-03-11
Adc Therapeutics Sa盘中异动 股价大跌5.16%报1.75美元
Adc Therapeutics Sa盘中异动 下午盘急速拉升5.62%
市场透视 · 2025-03-07
Adc Therapeutics Sa盘中异动 下午盘急速拉升5.62%
Adc Therapeutics Sa盘中异动 股价大跌5.59%
市场透视 · 2025-03-06
Adc Therapeutics Sa盘中异动 股价大跌5.59%
Adc Therapeutics Sa盘中异动 急速下挫5.68%报1.66美元
市场透视 · 2025-03-03
Adc Therapeutics Sa盘中异动 急速下挫5.68%报1.66美元
Adc Therapeutics Sa盘中异动 快速上涨5.13%报1.64美元
市场透视 · 2025-02-27
Adc Therapeutics Sa盘中异动 快速上涨5.13%报1.64美元
Adc Therapeutics Sa盘中异动 早盘股价大跌5.00%报1.52美元
市场透视 · 2025-02-26
Adc Therapeutics Sa盘中异动 早盘股价大跌5.00%报1.52美元
Stephens & Co.:维持ADC Therapeutics(ADCT.US)评级,由增持调整至增持评级, 目标价由6.00美元调整至8.00美元。
金融界 · 2025-02-24
Stephens & Co.:维持ADC Therapeutics(ADCT.US)评级,由增持调整至增持评级, 目标价由6.00美元调整至8.00美元。
Adc Therapeutics Sa盘中异动 大幅拉升5.00%
市场透视 · 2025-02-18
Adc Therapeutics Sa盘中异动 大幅拉升5.00%
Adc Therapeutics Sa盘中异动 大幅拉升5.90%报1.71美元
市场透视 · 2025-02-14
Adc Therapeutics Sa盘中异动 大幅拉升5.90%报1.71美元
Adc Therapeutics Sa盘中异动 股价大涨5.41%
市场透视 · 2025-02-14
Adc Therapeutics Sa盘中异动 股价大涨5.41%
Adc Therapeutics Sa盘中异动 早盘股价大跌5.44%报1.39美元
市场透视 · 2025-02-12
Adc Therapeutics Sa盘中异动 早盘股价大跌5.44%报1.39美元
Adc Therapeutics Sa盘中异动 下午盘股价大跌5.30%
市场透视 · 2025-02-11
Adc Therapeutics Sa盘中异动 下午盘股价大跌5.30%
加载更多
公司概况
公司名称:
ADC Therapeutics SA
所属市场:
NYSE
上市日期:
--
主营业务:
ADC Therapeutics SA于2011年6月6日根据瑞士法律注册成立。该公司是一家完全整合的商业阶段生物技术公司,通过下一代靶向抗体药物偶联物帮助改善癌症患者的生活。该公司的旗舰产品ZYNLONTA(loncastuximab tesirine或Lonca)于2021年4月23日获得FDA的加速批准,并在此后不久在美国上市,用于治疗经过两个或两个以上系统治疗的复发或难治性大B细胞淋巴瘤成人患者,包括未另行说明的弥漫性大B细胞淋巴瘤、由低级别淋巴瘤引起的DLBCL,以及高级别B细胞淋巴瘤。该公司的目标是将ZYNLONTA确立为三线+ DLBCL护理标准,同时探索ZYNLONTA在早期治疗和组合中的应用,以扩大市场机会。
发行价格:
--
{"stockData":{"symbol":"ADCT","market":"US","secType":"STK","nameCN":"ADC Therapeutics SA","latestPrice":4.18,"timestamp":1772485200000,"preClose":4.1,"halted":0,"volume":520829,"hourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.18,"latestTime":"16:40 EST","volume":3292,"amount":13760.56,"timestamp":1772487621408,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.019512195121951237,"floatShares":92240800,"shares":123877111,"eps":-1.441724,"marketStatus":"盘后交易","change":0.08,"latestTime":"03-02 16:49:40 EST","open":4.02,"high":4.22,"low":3.94,"amount":2150563.8779929997,"amplitude":0.068293,"askPrice":4.5,"askSize":20,"bidPrice":3.87,"bidSize":360,"shortable":3,"etf":0,"ttmEps":-1.441724,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772499600000},"marketStatusCode":4,"adr":0,"listingDate":1589515200000,"exchange":"NYSE","adjPreClose":4.1,"preHourTrading":{"tag":"盘前","latestPrice":4.03,"preClose":4.1,"latestTime":"09:22 EST","volume":34,"amount":133.0300048,"timestamp":1772461344826,"change":-0.07,"changeRate":-0.017073,"amplitude":0.034146},"postHourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.18,"latestTime":"16:40 EST","volume":3292,"amount":13760.56,"timestamp":1772487621408,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.709437,"impliedVol":0.9397,"impliedVolPercentile":0.2948},"requestUrl":"/m/hq/s/ADCT","defaultTab":"news","newsList":[{"id":"1109084963","title":"ADC Therapeutics SA:若发生控制权变更,收购方将继续支付特许权使用费直至达到原定上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1109084963","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109084963?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:19","pubTimestamp":1771849168,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA宣布,在控制权变更的情况下,收购方将继续向医疗保健特许权公司支付特许权使用费,直至达到原始约定的上限金额。这一安排确保了特许权收益的持续性,不受公司所有权结构变化的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ADCT"],"gpt_icon":0},{"id":"1191972270","title":"ADC Therapeutics SA预计2027年起实现显著增长,美国市场潜在年收入峰值或达6亿至10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191972270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191972270?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:17","pubTimestamp":1771849037,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA(简称ADCT)近日发布业绩展望,预计公司将从2027年开始进入实质性增长阶段。据分析,其在美国市场的潜在年收入峰值有望达到6亿美元至10亿美元区间。\n这一乐观预期基于公司核心产品管线的商业化进展及市场扩张策略。随着创新疗法逐步获得监管批准并扩大适应症,ADC Therapeutics有望在肿瘤治疗领域占据重要市场份额。\n公司管理层强调,这一增长轨迹依赖于临床开发计划的顺利执行以及市场渗透策略的有效实施。若各项进展符合预期,2027年后公司财务表现将迎来显著提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ADCT"],"gpt_icon":0},{"id":"1119850242","title":"ADC Therapeutics SA获医疗保健特许权公司授予认股权证 可购买约980万股普通股 行权价每股3.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119850242","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119850242?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:17","pubTimestamp":1771849034,"startTime":"0","endTime":"0","summary":"医疗保健特许权投资公司向ADC Therapeutics SA授予了约980万股普通股的认购权证。根据协议条款,每份权证的行权价格确定为每股3.81美元。此次权证授予将为ADC Therapeutics SA带来潜在的资本注入,同时为投资者提供了未来以固定价格购入该公司普通股的权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","ADCT","BK4139"],"gpt_icon":0},{"id":"2607095745","title":"Adc Therapeutics Sa盘中异动 早盘快速下跌5.01%报3.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607095745","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607095745?lang=zh_cn&edition=full","pubTime":"2026-01-28 23:01","pubTimestamp":1769612491,"startTime":"0","endTime":"0","summary":"北京时间2026年01月28日23时01分,Adc Therapeutics Sa股票出现异动,股价快速跳水5.01%。截至发稿,该股报3.41美元/股,成交量7.9999万股,换手率0.06%,振幅5.71%。Adc Therapeutics Sa股票所在的生物技术行业中,整体跌幅为0.85%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家商业阶段专注于肿瘤的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128230131953ec62d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128230131953ec62d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4007","BK4539","LENZ","BK4139","ADCT"],"gpt_icon":0},{"id":"1170493752","title":"ADC Therapeutics SA - 出售股东可能不时提供14,696,253股普通股 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1170493752","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170493752?lang=zh_cn&edition=full","pubTime":"2025-12-13 06:11","pubTimestamp":1765577470,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA - 出售股东可能不时提供14,696,253股普通股 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","ADCT"],"gpt_icon":0},{"id":"1122277823","title":"ADC Therapeutics 发布 Lotis-7 1B期临床试验的新数据,显示 Zynlonta® 与双特异性抗体联合使用的潜在最佳治疗方案,适用于复发/难治性大B细胞淋巴瘤患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1122277823","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122277823?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:30","pubTimestamp":1764765010,"startTime":"0","endTime":"0","summary":"ADC Therapeutics 发布 Lotis-7 1B期临床试验的新数据,显示 Zynlonta® 与双特异性抗体联合使用的潜在最佳治疗方案,适用于复发/难治性大B细胞淋巴瘤患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","BK4139","BK4505"],"gpt_icon":0},{"id":"1195658704","title":"ADC Therapeutics 2025财年Q3业绩会总结及问答精华:ZENLATA临床进展与市场扩展潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1195658704","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195658704?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:21","pubTimestamp":1762784502,"startTime":"0","endTime":"0","summary":"ADC Therapeutics管理层强调ZENLATA在第三线以上DLBCL患者中的差异化治疗选择,并持续推进关键试验数据。管理层计划在2026年公布LOTUS V试验的顶线结果,并在2027年进行补充BLA提交。问题3:ZENLATA是否考虑进入DLBCL的一线治疗?ADC Therapeutics在2025财年第三季度通过降低运营成本和私募融资延长现金流,继续推进ZENLATA的临床试验和市场扩展。管理层对未来的市场潜力持乐观态度,预计ZENLATA将在DLBCL的第二线及以上治疗中实现显著的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","ADC"],"gpt_icon":0},{"id":"1166212373","title":"ADC Therapeutics SA:截至9月30日的三个月和九个月内,重组、减值及其他相关费用分别为40万美元和1350万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166212373","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166212373?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:39","pubTimestamp":1762778375,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA:截至9月30日的三个月和九个月内,重组、减值及其他相关费用分别为40万美元和1350万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADCT","BK4505"],"gpt_icon":0},{"id":"2518099672","title":"Adc Therapeutics Sa盘中异动 股价大跌5.16%报1.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518099672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518099672?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:10","pubTimestamp":1741630242,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时10分,Adc Therapeutics Sa股票出现异动,股价急速跳水5.16%。截至发稿,该股报1.75美元/股,成交量14.2555万股,换手率0.15%,振幅4.35%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为0.69%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102104298a2d3e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102104298a2d3e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","ADCT","LENZ"],"gpt_icon":0},{"id":"2517192786","title":"Adc Therapeutics Sa盘中异动 下午盘急速拉升5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517192786","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517192786?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:49","pubTimestamp":1741290558,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时49分,Adc Therapeutics Sa股票出现异动,股价快速上涨5.62%。Adc Therapeutics Sa股票所在的生物技术行业中,整体跌幅为0.45%。其相关个股中,Plus Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Aeon Biopharma, Inc.涨幅较大,Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃,换手率分别为5163.60%、4474.05%、264.87%,振幅较大的相关个股有Plus Therapeutics, Inc.、Surrozen Inc C/Wts 01/08/2031 、Tonix Pharmaceuticals Holding Corp.,振幅分别为172.51%、127.10%、71.44%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034918989eeb10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034918989eeb10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","ADCT","LENZ"],"gpt_icon":0},{"id":"2517941825","title":"Adc Therapeutics Sa盘中异动 股价大跌5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517941825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517941825?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:17","pubTimestamp":1741191430,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时17分,Adc Therapeutics Sa股票出现异动,股价大幅跳水5.59%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为1.22%。其相关个股中,Chimerix, Inc.、Nutriband Inc C/Wts 、Oculis Holding Ag C/Wts 06/03/2028 涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为895.85%、291.89%、278.41%,振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ,振幅分别为82.59%、54.27%、41.26%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001711abe9d15d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001711abe9d15d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LENZ","ADCT"],"gpt_icon":0},{"id":"2516163203","title":"Adc Therapeutics Sa盘中异动 急速下挫5.68%报1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516163203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516163203?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:58","pubTimestamp":1741013906,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时58分,Adc Therapeutics Sa股票出现波动,股价大幅下跌5.68%。截至发稿,该股报1.66美元/股,成交量1.9903万股,换手率0.02%,振幅4.64%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为0.00%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225826a25d4829&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225826a25d4829&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADCT","BK4139","LENZ","BK4505"],"gpt_icon":0},{"id":"2514863067","title":"Adc Therapeutics Sa盘中异动 快速上涨5.13%报1.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514863067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514863067?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:17","pubTimestamp":1740590229,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时17分,Adc Therapeutics Sa股票出现波动,股价快速拉升5.13%。截至发稿,该股报1.64美元/股,成交量7.8446万股,换手率0.08%,振幅4.81%。Adc Therapeutics Sa股票所在的生物技术行业中,整体跌幅为0.03%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227011710abde11c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227011710abde11c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADCT","LENZ","BK4505","BK4139"],"gpt_icon":0},{"id":"2514201112","title":"Adc Therapeutics Sa盘中异动 早盘股价大跌5.00%报1.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514201112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514201112?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:27","pubTimestamp":1740500854,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时27分,Adc Therapeutics Sa股票出现异动,股价快速跳水5.00%。截至发稿,该股报1.52美元/股,成交量7.8271万股,换手率0.08%,振幅4.32%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为0.35%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002734a253a15b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002734a253a15b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4505","ADCT"],"gpt_icon":0},{"id":"2513729697","title":"Stephens & Co.:维持ADC Therapeutics(ADCT.US)评级,由增持调整至增持评级, 目标价由6.00美元调整至8.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729697","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513729697?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:22","pubTimestamp":1740403325,"startTime":"0","endTime":"0","summary":"Stephens & Co.:维持ADC Therapeutics(ADCT.US)评级,由增持调整至增持评级, 目标价由6.00美元调整至8.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24212248352457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADCT","LENZ","ADC"],"gpt_icon":0},{"id":"2512166105","title":"Adc Therapeutics Sa盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512166105?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:45","pubTimestamp":1739889906,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时45分,Adc Therapeutics Sa股票出现波动,股价大幅拉升5.00%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为0.73%。其相关个股中,Solid Biosciences Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大,Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃,换手率分别为305.91%、111.39%、89.11%,振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.,振幅分别为41.79%、34.04%、26.83%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224506a24aafc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224506a24aafc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","ADCT","LENZ"],"gpt_icon":0},{"id":"2511699767","title":"Adc Therapeutics Sa盘中异动 大幅拉升5.90%报1.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511699767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511699767?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:45","pubTimestamp":1739544305,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时45分,Adc Therapeutics Sa股票出现波动,股价急速拉升5.90%。截至发稿,该股报1.71美元/股,成交量2.2044万股,换手率0.02%,振幅2.48%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为0.33%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422450698858d0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422450698858d0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","ADCT","LENZ","BK4139"],"gpt_icon":0},{"id":"2511573817","title":"Adc Therapeutics Sa盘中异动 股价大涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511573817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511573817?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:37","pubTimestamp":1739468222,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日01时37分,Adc Therapeutics Sa股票出现异动,股价急速拉升5.41%。截至发稿,该股报1.56美元/股,成交量13.4904万股,换手率0.14%,振幅7.09%。Adc Therapeutics Sa股票所在的生物技术行业中,整体涨幅为1.04%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214013702a244d156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214013702a244d156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4505","ADCT"],"gpt_icon":0},{"id":"2510036339","title":"Adc Therapeutics Sa盘中异动 早盘股价大跌5.44%报1.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510036339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510036339?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:19","pubTimestamp":1739290766,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时19分,Adc Therapeutics Sa股票出现波动,股价急速跳水5.44%。截至发稿,该股报1.39美元/股,成交量22.0818万股,换手率0.23%,振幅4.83%。Adc Therapeutics Sa股票所在的生物技术行业中,整体跌幅为1.56%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212001926abcb1e06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212001926abcb1e06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ADCT","BK4505"],"gpt_icon":0},{"id":"2510089904","title":"Adc Therapeutics Sa盘中异动 下午盘股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510089904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510089904?lang=zh_cn&edition=full","pubTime":"2025-02-11 03:04","pubTimestamp":1739214276,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日03时04分,Adc Therapeutics Sa股票出现异动,股价快速跳水5.30%。截至发稿,该股报1.43美元/股,成交量26.9099万股,换手率0.28%,振幅5.30%。Adc Therapeutics Sa股票所在的生物技术行业中,整体跌幅为0.76%。Adc Therapeutics Sa公司简介:ADC Therapeutics SA是一家专注于肿瘤学商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211030437961e3331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211030437961e3331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LENZ","ADCT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adctherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1582},{"period":"3month","weight":-0.0465},{"period":"6month","weight":0.3355},{"period":"1year","weight":1.5949},{"period":"ytd","weight":0.1615}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ADC Therapeutics SA于2011年6月6日根据瑞士法律注册成立。该公司是一家完全整合的商业阶段生物技术公司,通过下一代靶向抗体药物偶联物帮助改善癌症患者的生活。该公司的旗舰产品ZYNLONTA(loncastuximab tesirine或Lonca)于2021年4月23日获得FDA的加速批准,并在此后不久在美国上市,用于治疗经过两个或两个以上系统治疗的复发或难治性大B细胞淋巴瘤成人患者,包括未另行说明的弥漫性大B细胞淋巴瘤、由低级别淋巴瘤引起的DLBCL,以及高级别B细胞淋巴瘤。该公司的目标是将ZYNLONTA确立为三线+ DLBCL护理标准,同时探索ZYNLONTA在早期治疗和组合中的应用,以扩大市场机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.12605},{"month":2,"riseRate":0.666667,"avgChangeRate":0.069601},{"month":3,"riseRate":0,"avgChangeRate":-0.185987},{"month":4,"riseRate":0.4,"avgChangeRate":-0.040442},{"month":5,"riseRate":0.4,"avgChangeRate":0.122666},{"month":6,"riseRate":0.5,"avgChangeRate":0.042888},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.072983},{"month":8,"riseRate":0.333333,"avgChangeRate":0.008214},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.079772},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.058531},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.016563},{"month":12,"riseRate":0.333333,"avgChangeRate":0.076305}],"exchange":"NYSE","name":"ADC Therapeutics SA","nameEN":"ADC Therapeutics SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADC Therapeutics SA(ADCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ADC Therapeutics SA(ADCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ADC Therapeutics SA,ADCT,ADC Therapeutics SA股票,ADC Therapeutics SA股票老虎,ADC Therapeutics SA股票老虎国际,ADC Therapeutics SA行情,ADC Therapeutics SA股票行情,ADC Therapeutics SA股价,ADC Therapeutics SA股市,ADC Therapeutics SA股票价格,ADC Therapeutics SA股票交易,ADC Therapeutics SA股票购买,ADC Therapeutics SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADC Therapeutics SA(ADCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ADC Therapeutics SA(ADCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}